Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36


Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study.

Li HH, Zuraw B, Longhurst HJ, Cicardi M, Bork K, Baker J, Lumry W, Bernstein J, Manning M, Levy D, Riedl MA, Feuersenger H, Prusty S, Pragst I, Machnig T, Craig T; COMPACT Investigators.

Allergy Asthma Clin Immunol. 2019 Aug 28;15:49. doi: 10.1186/s13223-019-0362-1. eCollection 2019.


Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

Craig T, Zuraw B, Longhurst H, Cicardi M, Bork K, Grattan C, Katelaris C, Sussman G, Keith PK, Yang W, Hébert J, Hanzlikova J, Staubach-Renz P, Martinez-Saguer I, Magerl M, Aygören-Pürsün E, Farkas H, Reshef A, Kivity S, Neri S, Crisan I, Caballero T, Baeza ML, Hernandez MD, Li H, Lumry W, Bernstein JA, Hussain I, Anderson J, Schwartz LB, Jacobs J, Manning M, Levy D, Riedl M, Christiansen S, Feuersenger H, Pragst I, Mycroft S, Pawaskar D, Jacobs I; COMPACT Investigators.

J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1793-1802.e2. doi: 10.1016/j.jaip.2019.01.054. Epub 2019 Feb 15.


Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.

Lumry WR, Craig T, Zuraw B, Longhurst H, Baker J, Li HH, Bernstein JA, Anderson J, Riedl MA, Manning ME, Keith PK, Levy DS, Caballero T, Banerji A, Gower RG, Farkas H, Lawo JP, Pragst I, Machnig T, Watson DJ.

J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1733-1741.e3. doi: 10.1016/j.jaip.2017.12.039. Epub 2018 Jan 31.


Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema.

Zhang Y, Tortorici MA, Pawaskar D, Pragst I, Machnig T, Hutmacher M, Zuraw B, Cicardi M, Craig T, Longhurst H, Sidhu J.

CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):158-165. doi: 10.1002/psp4.12271. Epub 2018 Jan 9.


Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.

Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, Li HH, Reshef A, Bonner J, Bernstein JA, Anderson J, Lumry WR, Farkas H, Katelaris CH, Sussman GL, Jacobs J, Riedl M, Manning ME, Hebert J, Keith PK, Kivity S, Neri S, Levy DS, Baeza ML, Nathan R, Schwartz LB, Caballero T, Yang W, Crisan I, Hernandez MD, Hussain I, Tarzi M, Ritchie B, Králíčková P, Guilarte M, Rehman SM, Banerji A, Gower RG, Bensen-Kennedy D, Edelman J, Feuersenger H, Lawo JP, Machnig T, Pawaskar D, Pragst I, Zuraw BL; COMPACT Investigators.

N Engl J Med. 2017 Mar 23;376(12):1131-1140. doi: 10.1056/NEJMoa1613627.


FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis.

May F, Krupka J, Fries M, Thielmann I, Pragst I, Weimer T, Panousis C, Nieswandt B, Stoll G, Dickneite G, Schulte S, Nolte MW.

Br J Haematol. 2016 Jun;173(5):769-78. doi: 10.1111/bjh.13990. Epub 2016 Mar 27.


The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats.

Krupka J, May F, Weimer T, Pragst I, Kleinschnitz C, Stoll G, Panousis C, Dickneite G, Nolte MW.

PLoS One. 2016 Jan 27;11(1):e0146783. doi: 10.1371/journal.pone.0146783. eCollection 2016.


Reconstituted high-density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component.

Herzog E, Pragst I, Waelchli M, Gille A, Schenk S, Mueller-Cohrs J, Diditchenko S, Zanoni P, Cuchel M, Seubert A, Rader DJ, Wright SD.

J Appl Toxicol. 2016 Aug;36(8):1038-47. doi: 10.1002/jat.3264. Epub 2015 Dec 9.


Utility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice.

Raquet E, Stockschlaeder M, Mueller-Cohrs J, Zollner S, Pragst I, Dickneite G.

Blood Coagul Fibrinolysis. 2015 Jul;26(5):515-21. doi: 10.1097/MBC.0000000000000269.


Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP).

Subramaniam S, Thielmann I, Morowski M, Pragst I, Sandset PM, Nieswandt B, Etscheid M, Kanse SM.

Thromb Haemost. 2015 Apr;113(4):870-80. doi: 10.1160/TH14-06-0519. Epub 2014 Nov 27.


Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.

Herzog E, Kaspereit F, Krege W, Doerr B, Mueller-Cohrs J, Pragst I, Morishima Y, Dickneite G.

Anesthesiology. 2015 Feb;122(2):387-98. doi: 10.1097/ALN.0000000000000520.


C1-esterase inhibitor treatment: preclinical safety aspects on the potential prothrombotic risk.

Schürmann D, Herzog E, Raquet E, Nolte MW, May F, Müller-Cohrs J, Björkqvist J, Dickneite G, Pragst I.

Thromb Haemost. 2014 Nov;112(5):960-71. doi: 10.1160/TH13-06-0469. Epub 2014 Aug 7.


Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.

Herzog E, Kaspereit FJ, Krege W, Doerr B, van Ryn J, Dickneite G, Pragst I.

Thromb Res. 2014 Sep;134(3):729-36. doi: 10.1016/j.thromres.2014.07.003. Epub 2014 Jul 11.


Recombinant fusion protein linking factor VIIa with albumin (rVIIa-FP): Tissue distribution in rats.

Herzog E, Harris S, McEwen A, Henson C, Pragst I, Dickneite G, Schulte S, Zollner S.

Thromb Res. 2014 Aug;134(2):495-502. doi: 10.1016/j.thromres.2014.05.031. Epub 2014 May 29.


Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.

Zollner S, Raquet E, Claar P, Müller-Cohrs J, Metzner HJ, Weimer T, Pragst I, Dickneite G, Schulte S.

Thromb Res. 2014 Jul;134(1):125-31. doi: 10.1016/j.thromres.2014.03.028. Epub 2014 Mar 19.


Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats.

Herzog E, Harris S, Henson C, McEwen A, Schenk S, Nolte MW, Pragst I, Dickneite G, Schulte S, Zollner S.

Thromb Res. 2014 May;133(5):900-7. doi: 10.1016/j.thromres.2014.02.010. Epub 2014 Feb 22.


Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).

Zollner S, Schuermann D, Raquet E, Mueller-Cohrs J, Weimer T, Pragst I, Dickneite G, Schulte S.

J Thromb Haemost. 2014 Feb;12(2):220-8. doi: 10.1111/jth.12477.


A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.

Larsson M, Rayzman V, Nolte MW, Nickel KF, Björkqvist J, Jämsä A, Hardy MP, Fries M, Schmidbauer S, Hedenqvist P, Broomé M, Pragst I, Dickneite G, Wilson MJ, Nash AD, Panousis C, Renné T.

Sci Transl Med. 2014 Feb 5;6(222):222ra17. doi: 10.1126/scitranslmed.3006804.


Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma.

Komenda M, Stadler D, Malinas T, Moses M, Pragst I, Herzog E, Schmutz P, Minnig K, El Menyawi I.

Vox Sang. 2014 Jul;107(1):26-36. doi: 10.1111/vox.12119. Epub 2013 Dec 13.


Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.

Diditchenko S, Gille A, Pragst I, Stadler D, Waelchli M, Hamilton R, Leis A, Wright SD.

Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2202-11. doi: 10.1161/ATVBAHA.113.301981. Epub 2013 Jul 18.


Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.

Zollner SB, Raquet E, Müller-Cohrs J, Metzner HJ, Weimer T, Pragst I, Dickneite G, Schulte S.

Thromb Res. 2013 Aug;132(2):280-7. doi: 10.1016/j.thromres.2013.06.017. Epub 2013 Jul 5.


Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.

Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J.

J Thromb Haemost. 2012 Sep;10(9):1841-8. doi: 10.1111/j.1538-7836.2012.04859.x.


Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

Nolte MW, Nichols TC, Mueller-Cohrs J, Merricks EP, Pragst I, Zollner S, Dickneite G.

J Thromb Haemost. 2012 Aug;10(8):1591-9. doi: 10.1111/j.1538-7836.2012.04826.x.


Medetomidine/midazolam/ketamine anaesthesia in ferrets: effects on cardiorespiratory parameters and evaluation of plasma drug concentrations.

Schernthaner A, Lendl CE, Hartmann K, Pragst I, Preissel AK, Henke J.

Vet Anaesth Analg. 2011 Sep;38(5):439-50. doi: 10.1111/j.1467-2995.2011.00635.x.


Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model.

Kaspereit F, Hoffmann S, Pragst I, Dickneite G.

Br J Anaesth. 2010 Nov;105(5):576-82. doi: 10.1093/bja/aeq216. Epub 2010 Aug 17.


Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model.

Pragst I, Kaspereit F, Dörr B, Dickneite G.

Thromb Res. 2010 Mar;125(3):272-7. doi: 10.1016/j.thromres.2009.10.011. Epub 2009 Nov 14.


Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P).

Dickneite G, Pragst I, Joch C, Bergman GE.

Blood Coagul Fibrinolysis. 2009 Oct;20(7):535-40. doi: 10.1097/MBC.0b013e32832da1c5. Review.


Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model.

Dickneite G, Pragst I.

Br J Anaesth. 2009 Mar;102(3):345-54. doi: 10.1093/bja/aen391. Epub 2009 Jan 24.


Effects of two Gbetagamma-binding proteins--N-terminally truncated phosducin and beta-adrenergic receptor kinase C terminus (betaARKct)--in heart failure.

Li Z, Laugwitz KL, Pinkernell K, Pragst I, Baumgartner C, Hoffmann E, Rosport K, Münch G, Moretti A, Humrich J, Lohse MJ, Ungerer M.

Gene Ther. 2003 Aug;10(16):1354-61.


Local photodynamic therapy reduces tissue hyperplasia after stenting in an experimental restenosis model.

Valassis G, Pragst I, Adolfs C, Paclik D, Wiens F, Vogel-Wiens C, Milz S, Gonschior P.

Basic Res Cardiol. 2002 Mar;97(2):132-6.


Blocking caspase-activated apoptosis improves contractility in failing myocardium.

Laugwitz KL, Moretti A, Weig HJ, Gillitzer A, Pinkernell K, Ott T, Pragst I, Städele C, Seyfarth M, Schömig A, Ungerer M.

Hum Gene Ther. 2001 Nov 20;12(17):2051-63.


Comparison of three different medetomidine/ketamine combinations in NMRI mice.

Kilic N, Henke J, Pragst I, Erhardt W.

Vet Anaesth Analg. 2001 Oct;28(4):211-212. doi: 10.1046/j.1467-2987.2001.00064.x-i3. Epub 2016 Nov 15. No abstract available.


Gene transfer of heterologous G protein-coupled receptors to cardiomyocytes: differential effects on contractility.

Laugwitz KL, Weig HJ, Moretti A, Hoffmann E, Ueblacker P, Pragst I, Rosport K, Schömig A, Ungerer M.

Circ Res. 2001 Apr 13;88(7):688-95.


High-resolution MR angiography: results in diseased arteries.

Gonschior P, Pragst I, Valassis G, Vogel-Wiens C, Huber A.

J Invasive Cardiol. 2001 Feb;13(2):151-7; discussion 158-70.


Pre- versus post-operative administration of buprenorphine as part of a reversible anaesthetic technique in rats.

Henke J, Perantoni D, Pragst I, Erhardt W.

Vet Anaesth Analg. 2000 Jul;27(2):117. doi: 10.1046/j.1467-2995.2000.00018-7.x. Epub 2016 Nov 16. No abstract available.


[Telemetric impedance analysis of the liver: evaluation of a noninvasive device for diagnosis of acute graft rejection after experimental liver transplantation].

Harms J, Schneider A, Hess U, Pragst I, Henke J, Busch R, Böttcher K.

Biomed Tech (Berl). 2000 Mar;45(3):43-50. German.


Supplemental Content

Loading ...
Support Center